ITP
Iron Triangle Partners Portfolio holdings
AUM
$632M
This Quarter Return
+22.34%
1 Year Return
+26.53%
3 Year Return
+134.07%
5 Year Return
+312.1%
10 Year Return
–
AUM
$558M
AUM Growth
+$558M
(-2.5%)
Cap. Flow
-$64.3M
Cap. Flow
% of AUM
-11.52%
Top 10 Holdings %
Top 10 Hldgs %
63.48%
Holding
36
New
9
Increased
4
Reduced
13
Closed
10
Top Buys
| 1 |
Universal Health Services
UHS
|
$42.3M |
| 2 |
Cooper Companies
COO
|
$40.7M |
| 3 |
Gilead Sciences
GILD
|
$32.1M |
| 4 |
Icon
ICLR
|
$27.4M |
| 5 |
Surgery Partners
SGRY
|
$20.3M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$30.5M |
| 2 |
HealthEquity
HQY
|
$29.6M |
| 3 |
Cigna
CI
|
$27.5M |
| 4 |
Guardant Health
GH
|
$26.2M |
| 5 |
HCA Healthcare
HCA
|
$25.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Icon
ICLR
$13.8B
| $43.7M | 7.84% | 225,000 +141,202 | +169% | +$27.4M |
|
2
Charles River Laboratories
CRL
$8.04B
| $43.6M | 7.81% | 200,000 -2,000 | -1% | -$436K |
|
|
3
Universal Health Services
UHS
$11.6B
| $42.3M | 7.58% | +300,000 | New | +$42.3M |
|
|
4
Cooper Companies
COO
$13.4B
| $40.7M | 7.29% | +123,000 | New | +$40.7M |
|
|
5
Surgery Partners
SGRY
$2.91B
| $35.7M | 6.39% | 1,280,000 +730,000 | +133% | +$20.3M |
|
|
6
Gilead Sciences
GILD
$140B
| $32.1M | 5.75% | +373,569 | New | +$32.1M |
|
7
Sanofi
SNY
$121B
| $31.5M | 5.64% | 650,000 -250,000 | -28% | -$12.1M |
|
8
Repligen
RGEN
$6.88B
| $30.1M | 5.4% | 178,000 +78,000 | +78% | +$13.2M |
|
9
Boston Scientific
BSX
$156B
| $27.8M | 4.98% | 600,000 -100,000 | -14% | -$4.63M |
|
10
Establishment Labs
ESTA
$1.2B
| $26.7M | 4.79% | 407,074 +84,796 | +26% | +$5.57M |
|
11
Inspire Medical Systems
INSP
$2.77B
| $20.2M | 3.61% | 80,000 -20,000 | -20% | -$5.04M |
|
12
United Therapeutics
UTHR
$13.8B
| $19.9M | 3.57% | +71,576 | New | +$19.9M |
|
|
13
Cigna
CI
$80.3B
| $19.9M | 3.56% | 60,000 -83,010 | -58% | -$27.5M |
|
14
Intuitive Surgical
ISRG
$170B
| $18.6M | 3.33% | +70,000 | New | +$18.6M |
|
15
Acadia Healthcare
ACHC
$2.12B
| $16.5M | 2.95% | 200,000 -150,000 | -43% | -$12.3M |
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $14M | 2.5% | 107,749 -42,251 | -28% | -$5.47M |
|
17
Pacific Biosciences
PACB
$393M
| $13.9M | 2.49% | 1,700,000 -1,300,000 | -43% | -$10.6M |
|
18
DexCom
DXCM
$29.5B
| $13.6M | 2.44% | 120,080 -29,920 | -20% | -$3.39M |
|
|
NARI
19
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $12.1M | 2.17% | 190,000 -110,000 | -37% | -$6.99M |
|
|
20
Neurocrine Biosciences
NBIX
$13.8B
| $12M | 2.14% | 100,089 -255,512 | -72% | -$30.5M |
|
21
Syndax Pharmaceuticals
SNDX
$1.41B
| $9.42M | 1.69% | +370,294 | New | +$9.42M |
|
22
Amylyx Pharmaceuticals
AMLX
$836M
| $8.88M | 1.59% | +240,240 | New | +$8.88M |
|
|
RXDX
23
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $8.25M | 1.48% | +75,000 | New | +$8.25M |
|
24
908 Devices
MASS
$226M
| $6.67M | 1.2% | 874,731 -25,269 | -3% | -$193K |
|
25
Karyopharm Therapeutics
KPTI
$61.7M
| $6.55M | 1.17% | +1,926,782 | New | +$6.55M |
|